Omg, 2012 last appraisal, same drug same application areas same everything except we now have Merck and Schenzen for prostate cancer partnerships, that significantly will increase the old
Appraisal and yes just breast cancer as published was over 300 mill just breast, now add on the partnerships which we didn’t have then.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links